Medication identification: What is the difference between mobosetinib and mobosetinib?

Mobocertinib (Mobocertinib) and mobocertinib are actually the same drug, they just have different names. Mobosetinib is an oral tyrosine kinase inhibitor (EGFR TKI) used to treat non-small cell lung cancer (NSCLC) with EGFR gene mutations. The mechanism of action of mobosetinib is to block the EGFR signaling pathway by inhibiting tyrosine kinase, thereby inhibiting tumor growth and spread.

Mobosetinib is an EGFR inhibitor that preferentially targets exon 20 insertion mutation variants. It is available as an oral capsule that can be taken once daily with or without food. Mobosetinib can cause a concentration-dependent prolongation of the QTc interval, which may lead to life-threatening complications such as torsade de pointes. Patients with baseline risk factors for QTc prolongation should have alternative agents considered or carefully monitored throughout treatment. Concomitant use of QTc-prolonging drugs with CYP3A inhibitors should be avoided as these drugs may increase mobotinib concentrations, thereby increasing the risk of QTc prolongation.

Mobosetinib The original drug has been launched in China, but it is not included in the medical insurance. The price of the common specification 40mg*112 pills per box is about 40,000 yuan, which is very high. The Hong Kong clinical version specification 40mg*30 pills per box is priced at more than 7,000 yuan (the price may fluctuate due to exchange rates). Generic drugs of Mobotinib have also been put on the market for sale overseas. Its pharmaceutical ingredients are basically the same as those of the original drugs at home and abroad. For example, the production specifications of Laos Pharmaceutical Factory 40mg*120 pills per box may be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.